Galangin, a novel dietary flavonoid, attenuates metastatic feature via PKC/ERK signaling pathway in TPA-treated liver cancer HepG2 cells by Shang-Tao Chien et al.
Chien et al. Cancer Cell International  (2015) 15:15 
DOI 10.1186/s12935-015-0168-2PRIMARY RESEARCH Open AccessGalangin, a novel dietary flavonoid, attenuates
metastatic feature via PKC/ERK signaling pathway
in TPA-treated liver cancer HepG2 cells
Shang-Tao Chien1,2, Ming-Der Shi3,4, Yi-Chieh Lee5,6, Chou-Chia Te6 and Yuan-Wei Shih6,7*Abstract
Background: Galangin (3,5,7-trihydroxyflavone) is a flavonoid compound found in high concentration in lesser
galangal. The objective of this study was to investigate the ability of galangin to inhibit 12-O-tetradecanoylphorbol-
13-acetate (TPA)-induced the invasion and metastasis of HepG2 liver cancer cells.
Results: First, using a cell-matrix adhesion assay, immunofluorescence assay, transwell-chamber invasion/migration
assay, and wound healing assay, we observed that galangin exerted an inhibitory effect on TPA-induced cell adhesion,
morphology/actin cytoskeleton arrangement, invasion and migration. Furthermore, the results of gelatin zymography
and reverse transcriptase polymerase chain reaction (RT-PCR) assays showed that galangin reduced the TPA-induced
enzyme activity of matrix metalloproteinase-2 (MMP-2) and matrix metalloproteinase-9 (MMP-9) in HepG2 cells; moreover,
the messenger RNA level was downregulated. We also observed through a Western blotting assay that galangin strongly
inhibited the TPA-induced protein expressions of protein kinase Cα (PKCα), protein kinase Cδ (PKCδ), phosphorylated
extracellular signal-regulated kinase 1/2 (ERK1/2), the phospho-inhibitor of kappaBα (phospho-IκBα), c-Fos, c-Jun, and
nuclear factor kappa B (NF-κB). Next, galangin dose-dependently inhibited the binding ability of NF-κB and activator protein
1 (AP-1) to MMP-2/MMP-9 promoters, respectively, resulting in the suppression of MMP-2/MMP-9 enzyme activity.
Conclusions: The results revealed that galangin effectively inhibited the TPA-induced invasion and migration of HepG2
cells through a protein kinase C/extracellular signal-regulated kinase (PKC/ERK) pathway. Thus, galangin may have
widespread applications in clinical therapy as an anti-metastatic medicament.
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Malignant neoplasm, generally known as cancer, is cur-
rently considered one of the most deadly types of dis-
eases. The leading cause of death in patients with cancer
is tumour metastasis. Hepatocellular carcinoma (HCC)
is amongst the most common types of malignant tu-
mours in the tropics and East Asian countries, including
Taiwan. Surgical resection remains the treatment of choice,
but because of the high rate of metastasis and poor progno-
ses, the number of deaths is almost the same as the number* Correspondence: shih723@seed.net.tw
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unless otherwise stated.of new cases occurring each year worldwide [1]. Metasta-
sis of HCC to distinct sites or organs, such as the lymph
nodes, lungs, spleen, peritoneum, and bones, is a major
cause of death [2].
Tumour metastasis is a complex process during which
cancer cells undergo a series of alterations at intracellular
and extracellular levels, including changes that (1) damage
intercellular interaction, (2) increase cancer cells and
extracellular matrix (ECM) interaction, (3) damage ECM
components, and (4) increase the invasion and migration
of cancer cells. In addition, metastasis involves the over-
expression of proteolytic enzymes, such as matrix metallo-
proteinases (MMPs) [3]. MMPs are enzymes involved
in ECM degradation in physiological processes, such as
tissue remodelling and embryonic development. Studies
have shown that MMP-2 and MMP-9 are particularly
crucial in tumour metastasis, the process of whichThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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more, TPA is a diester of phorbol and a potent tumour
promoter often employed in biomedical research to ac-
tivate the signal transduction enzyme PKC [6]. PKC iso-
forms comprise a family of serine/threonine kinases that
can be activated as major signalling transduction en-
zymes to respond to extracellular signals, such as those
by diacylglycerol and calcium ions, that are generated
by ligand-receptor interactions with the nucleus at the
cell surface [7]. In addition, PKC isoforms are involved
in signalling transduction pathways for numerous bio-
logical processes, such as proliferation, survival, angio-
genesis, metastasis, and tumourigenesis [8-10]. Previous
studies has demonstrated that TPA controls the ex-
pressions of MMPs by modulating the activation of
transcription factors, such as NF-kB and AP-1, through
phosphatidylinositide-3 kinase/Akt (PI3K/Akt), c-Jun
N-terminal kinase (JNK), p38, and ERK signalling path-
ways [11]. PI3K activation leads to the phosphorylation of
phosphatidyl-inositides, which activates the primary
downstream target Akt that apparently plays various cru-
cial roles in regulating cellular growth, differentiation, ad-
hesion, inflammatory reactions, and invasion [12,13].
Three major mammalian mitogen-activated protein ki-
nases (MAPKs) are ERK, JNK, and p38. Various MAPKs
are activated in response to different extracellular stimuli
and have distinct downstream targets, thus serving unique
roles in cellular responses. The activation of MAPKs has
been shown in other systems to be the mechanism crucial
for promoting the production of MMPs, which are vital
for cell proliferation, invasion, and neovascularization
[14-16]. In addition, the gene expressions of MMPs are
primarily regulated by transcriptional factors, such as NF-
κB and AP-1 (a heterodimer consisting of protein mole-
cules from the Fos and Jun protein families).
Galangin is a naturally occurring flavonoid found in
Alpinia officinarum (lesser galangal). Flavonoids are well
known antioxidants, which can protect cells from being
damaged by free radicals [17-19], and are believed to exert
inhibitory effects on cancer cells [20,21]. Previous studies
have demonstrated that galangin exhibits anti-proliferative
and apoptotic effects on the growth of cancer cells that
originate from human leukemia cells [22,23]. Although
galangin may inhibit the growth of various cancers by in-
ducing antiproliferation and apoptosis in cancer cells, the
precise effect and related molecular mechanism of galan-
gin involved in the TPA-induced metastatuc feature of
HepG2 liver cancer cells remains unclear.
Material and methods
Reagents and antibodies
Galangin (purity ≥ 99%) was purchased from Extrasynthese
(Genay, France); dimethylsulfoxide (DMSO), Tris–HCl,
ethylenediaminetetraacetic acid (EDTA), sodium dodecylsulphate (SDS), phenylmethylsulfonyl fluoride, bovine
serum albumin (BSA), gelatin, leupeptin, Nonidet P-40,
deoxycholic acid and sodium orthovanadate were pur-
chased from Sigma-Aldrich Chemical Co. (St. Louis, MO,
USA); A protein assay kit was obtained from Bio-Rad
Labs. (Hercules, CA, USA). Dulbecco’s phosphate buffer
solution (PBS), fetal bovine serum (FBS), trypsin-EDTA,
and powdered Dulbecco’s modified Eagle’s medium
(DMEM) were purchased from Gibco-BRL (Gaithersburg,
MD, USA). Matrigel was obtained from BD Transduction
Laboratories (San Diego, CA, USA). Antibodies against
Akt, ERK1/2, JNK/SAPK, and p38 MAPK, proteins, and
phosphorylated proteins were purchased from Cell Signal-
ling Technology (Beverly, MA, USA). An enhanced
chemiluminescence (ECL) kit was purchased from
Amersham Life Science (Amersham, UK).Cell culture and galangin treatment
Human nonmalignant Chang liver cells, human hepato-
cellular carcinoma HepG2 cells, and human hepatocellu-
lar carcinoma Hep3B cells were maintained in DMEM
medium. Human gastric adenocarcinoma AGS cells was
maintained in RPMI-1640 medium. Above-mentioned
cell lines were obtained from BCRC (Bioresource Collec-
tion and Research Center in Hsin-Chu, Taiwan). All cells
were cultured at 37°C in a humidified atmosphere of 5%
CO2-95% air. In a medium supplemented with 10% FBS
and antibiotics (100 U/ml of penicillin and 100 mg/ml of
streptomycin). Adherent cells were detached through in-
cubation with trypsin. For galangin treatment, the stock
solution of galangin was dissolved in DMSO and steri-
lised through filtration by using 0.2-μm disc filters. Ap-
propriate amounts of the stock solution (10 mg/ml in
DMSO) of galangin were added to the cultured medium
to achieve the indicated concentrations.Cell viability (MTT assay)
To measure the effect of galangin on cell viability, the
Chang liver, AGS, Hep3B, and HepG2 cells were seeded
in 24-well plates (1 × 105 cells/well) for 16–18 h. The
cells were treated with or without various concentrations
of galangin (0, 1, 2.5, 5, 10, 15, 20, 25, and 30 μM) for
24 h and 48 h. Treatment at each concentration was re-
peated three times. To further investigate whether galan-
gin and/or TPA influence cell viability, HepG2 cells were
treated with the presence or absence of drugs (70 nM
TPA and 5 μM galangin) for 24 h. After the exposure
period, the medium was removed and the cells were
washed with PBS. The medium was changed, incubated
with an MTT solution (5 mg/ml/well) for 4 h, and then
removed. Formazan was solubilised in isopropanol and
measured spectrophotometrically at 563 nm. The per-
centage of viable cells was estimated by comparing the
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untreated control cells.
Cell-matrix adhesion assay
HepG2 cells were pretreated with 70 nM TPA and incu-
bated in various concentrations of galangin (0, 1, 2.5,
and 5 μM) for 24 h. The cells were seeded at a density
of 1 × 105 cells/ml in a 24-well plate, coated with 500 μl
of type IV collagen (10 μg/ml), and cultured for 30 min.
Nonadherent cells were removed by using PBS washes,
and adherent cells were fixed in ethanol. After being
stained with 0.1% crystal violet, the fixed cells were lysed
in 0.2% Triton X-100, and measured spectrophotomet-
rically at 550 nm.
Immunofluorescence assay
To determine the effect of galangin on cell morphology
and actin stress fibers, HepG2 cells (4 × 105 cells/well)
were plated in 6-well plates, grown for 16–18 h, stimu-
lated with 70 nM TPA for 12 h, and incubated in various
concentrations of galangin (0, 1, 2.5, and 5 μM) for 24 h.
After the exposure period, the medium was removed,
and the cells were washed with Ca2+/Mg2+ free PBS. The
cells were then fixed with 4% paraformaldehyde in
Ca2+/Mg2+− free PBS for 15 min and incubated with
0.5% Triton X-100 in Ca2+/Mg2+ free PBS for 5 min.
The cells were incubated with 1% BSA and 0.5% Triton
X-100 in Ca2+/Mg2+− free PBS for 1 h (blocking) and then
incubated with 200 U/ml Alexa flour 488-phallodin for
1 h to stain the actin filaments. Fluorescent images were
captured using a BX51 fluorescence microscope (Olympus,
Tokyo, Japan).
Transwell-chamber invasion and migration assay
The invasion assay was performed by using Hanging Cell
Culture-inserts (BD Biosciences; pore size, 8 μm) in a
6-well plate. The ability of HepG2 cells to pass through
filters coated with Matrigel was measured using a
transwell-chamber invasion assay. Matrigel was diluted
to 200 μg/ml with distilled cold-filtered water and ap-
plied to the upper surface of the filter inserts. Briefly,
HepG2 cells were stimulated with 70 nM TPA for 12 h
and incubated in various concentrations of galangin (0,
1, 2.5, and 5 μM) for 24 h. After 24 h, the cells were de-
tached using trypsin and resuspended in a serum-free
medium. A medium containing 10% FBS medium was
applied to the lower chamber as a chemoattractant,
and cells were seeded on the upper filter at a density of
1 × 105 cells/ml in the serum-free medium. The 6-well
plate was incubated for 24 h at 37°C in 5% CO2, the fil-
ter inserts were removed from the wells, and the cells
on the upper surface of the filter were wiped with a
cotton-tipped swab. Filters were fixed with methanol
for 10 min and stained with Giemsa dye for 1 h. Thecells that invaded the lower surface of the filter were
counted under a light microscope. The data were
expressed as the average number of cells attached to
the bottom surface from randomly chosen fields. Each
experiment was conducted in triplicate.
To measure the migrative ability of HepG2 cells, cells
were seeded on the upper surface of the filter inserts with
8-μm pore polycarbonate filters that were not coated with
Matrigel. The migrative cells were treated and measured
as described in the invasion assay.
Wound healing assay
To determine cell motility, HepG2 cells (1 × 105 cells/ml)
were seeded in a 6-well tissue culture plate by using
DMEM medium containing 10% FBS and grown to 80-
90% confluence. After the medium was aspirated, the
center of the cell monolayer was scraped using a sterile
micropipette tip to create a denuded zone (gap) featur-
ing an even width. Subsequently, cellular debris was
washed with PBS, and the HepG2 cells were pretreated
with 70 nM TPA for 12 h and incubated in various
concentrations of galangin (0, 1, 2.5, and 5 μM) for
24 h. Wound closure was monitored and photographed
using an Olympus CKX-41 inverted microscope and an
Olympus E-410 camera. To quantify the migrated cells,
pictures of the initial wounded monolayers were com-
pared with the corresponding pictures of cells at the
end of the incubation period. Artificial lines that corre-
sponded to the cutting edges were drawn on pictures of
the original wounds and overlain on the pictures of the
cultures after incubation. Cells that migrated across white
lines were counted in 6 random fields from each triplicate
treatment; data were presented as the mean ± standard
deviation (SD).
Gelatin zymography assay
The activities of MMP-2 and MMP-9 were assayed by
gelatin zymography. HepG2 cells (4 × 105 cells/well)
were plated in 6-well plates, stimulated with 70 nM TPA
for 12 h, and incubated in various concentrations of
galangin (0, 1, 2.5, and 5 μM) for 24 h. The conditioned
medium was collected and gelatin zymography was per-
formed to examine the activities of MMP-2 and MMP-9.
Samples were mixed with a loading buffer and electro-
phoresed on an 8% SDS-polyacrylamide gel containing
0.1% gelatin. Electrophoresis was performed at 140 and
110 V for 3 h. Gels were washed twice with a zymography
washing buffer (2.5% Triton X-100 in double-distilled
H2O) at room temperature to remove SDS. The cells
were incubated at 37°C for 12–16 h in zymography reac-
tion buffer (40 mM Tris–HCl (pH 8.0), 10 mM CaCl2,
0.02% NaN3), stained with Coomassie blue R-250
(0.125% Coomassie blue R-250, 0.1% amino black, 50%
methanol, 10% acetic acid) for 1 h, and destained with a
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double-distilled H2O). Nonstaining bands representing
the levels of the latent forms of MMP-2 and MMP-9
were quantified through densitometer measurement by
using a digital imaging analysis system.
Isolation of total RNA, reverse transcriptase polymerase
chain reaction (RT-PCR), and DNA electrophoresis
Total RNA was isolated from HepG2 cells by using the
total RNA Extraction Midiprep System (Viogene Bio-Tek
Corporation, Taiwan). Total RNA (2 μg) was transcribed
to 20 μl cDNA with 1 μl dNTPs (2.5 mM), 1 μl oligo dT
(10 pmole/μl), and 1 μl RTase (200 U), 1 μl RNase in-
hibitor and 5× reaction buffer. The appropriate primers
(sense of MMP-2, 5′-GGCCCTGTCACTCCTGAGAT-3′,
nt 1337–1356; antisense of MMP-2, 5′-GGCATCCAGGT
TATCGGGGA-3′, nt 2026–2007; sense of MMP-9, 5′-
AGGCCTCTACAGAGTCTTTG-3′, nt 1201–1220; anti-
sense of MMP-9, 5′-CAGTCCAACAAGAAAGGACG-3′,
nt 1700–1683; sense of GADPH, 5′-CGGAGTCAACGG
ATTGGTGTT-3′, nt 94–126; antisense of 5′-AGCCT
TCTCCATGGTTGGTGAAGAC-3′, nt 399–375) were
used for PCR amplifications. The PCR was performed
by using Platinum Taq polymerase (Invitrogen) under
the following conditions: 30 cycles at 94°C for 1 min, 59°C
(MMP-2) or 60°C (MMP-9 and GAPDH) for 1 min, 72°C
for 1 min, and 72°C for 10 min.
Western blotting assay
The membrane as well as cytosolic and nuclear fractions
of cells were prepared as described previously [24]. Western
blotting was performed as follows. Denatured samples
(50 μg extracted protein) were resolved on 10-12% SDS-
PAGE gels. The proteins were transferred onto nitrocellu-
lose membranes. Nonspecific binding of the membranes
was blocked with Tris-buffered saline (TBS) containing
1% (w/v) nonfat dry milk and 0.1% (v/v) Tween-20
(TBST) for longer than 2 h. Membranes were washed 3
times with TBST for 10 min and incubated with an appro-
priate dilution of specific primary antibodies in TBST
overnight at 4°C. The membranes were then washed with
TBST and incubated with secondary antibody (i.e., horse-
radish peroxidase-conjugated goat antimouse or antirabbit
immunoglobulin G) for 1 h. After the membranes were
again washed three times in TBST for 10 min, the bands
were detected by performing ECL by using ECL Western
blotting detection reagents and exposed ECL hyperfilm in
a FUJFILM Las-3000 mini image-analysis system (Tokyo,
Japan). Proteins were quantitatively determined through
densitometry by using FUJFILM-Multi Gauge V3.0 software.
Electrophoretic mobility shift assay
Cell nuclear proteins were extracted using a nuclear
extract buffer and measured using an electrophoreticmobility shift assay (EMSA). Cells (1 × 105/ml) were col-
lected in a PBS buffer (pH 7.4) and centrifuged at 2000 g
for 5 min at 4°C. The cells were lysed with buffer A
(10 mM HEPES, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM
DTT, and 0.5 mM PMSF〔pH 7.9〕 containing 5% NP-40)
for 10 min on ice and were subsequently subjected to
vortexing to shear the cytoplasmic membranes. The ly-
sates were centrifuged at 2000 g for 10 min at 4°C. The
pellet containing the nuclei was extracted using high salt
buffer B (20 mM HEPES, 420 mM NaCl, 1.5 mM MgCl2,
0.5 mM DTT, 0.5 mM PMSF, 0.2 mM EDTA, and 25%
glycerol) for 15 min on ice. The lysates were centrifuged
at 13000 g for 10 min at 4°C. The supernatant containing
the nuclear proteins was collected and frozen at −80°C
until use. The protein content of nuclear fractions was de-
termined using the Bio-Rad protein assay. A 5 μg aliquot
of nuclear proteins was mixed with biotin-labeled NF-κB
or AP-1 oligonucleotide probes for 15 min at room
temperature or with oligonucleotides (sense of NF-κB, 5′-
AGTTGAGGGGACTTTCCCAGGC-3′, antisense of NF-
κB, 3′-TCAACTCCCCTGAAAGGGTCCG-5′; sense of
AP-1, 5′-CGCTTGATGACTCAGCCGGAA-3′, antisense
of AP-1, 3′-GCGAACTACTGAGTCGGCCTT-5′). DNA
probes were added to 10 μl binding reactions containing
double-distilled H2O, 5 μg nuclear proteins, 1 μl poly
(dI-dC), 1 μl biotin-labeled double stranded NF-κB or
AP-1 oliginucleotides, and 2 μl of 10-fold binding buffer
into a microcentrifuge tube and incubated for 15 min at
room temperature. Specific competition binding assays
were performed by adding 200-fold excess of unlabeled
probe as a specific competitor. After protein-DNA com-
plexes formation, samples were loaded onto a 6% non-
denaturing polyacrylamide gel in a 0.5% TBE buffer and
transferred to positively charged nitrocellulose membranes
(Milipore, Bedford, MA) by usng a transfer blotting appar-
atus, and crosslinked in a Stratagene crosslinker. Gel shifts
were visualised by first using streptavidin-horseradish per-
oxidase and then chemiluminescent detection.
Statistical analysis
Data were expressed as the means ± SD of three independ-
ent experiments and analysed using the Student’s t-test
(Sigmaplot 2001, SPSS Inc., Chicago, IL, USA). Significant
differences were established at P ≤ 0.05.
Results
Galangin inhibits the viability of HepG2, Hep3B, and AGS
cells
Figure 1A lists the chemical structure of galangin. In this
study, we first examined the effect of galangin on cell
viability in four cell lines, Chang liver, AGS, Hep3B, and
HepG2 cells. As shown in Figure 1B, galangin exhibited
a dose- and time-dependent inhibitory effect on the cell
viability of four cancer cell lines. The strongest potency
Figure 1 Effect of galangin on the viability in four cell lines, Chang liver, AGS, Hep3B, and HepG2 cells. (A) Chemical structure of
galangin. (B) Four cell lines were treated with or without various concentrations of galangin (0, 1, 2.5, 5, 10, 15, 20, 25, and 30 μM) for 24 and
48 h, separately. (C) HepG2 cells were treated with or without of drugs (70 nM TPA and 5 μM galangin) for 24 and 48 h. Thereafter, cell viability
was determined by MTT assay. The survival cell number was directly proportional to formazan, which was measured spectrophotometrically at
563 nm. Values represent mean ± SD of three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001 compared with the untreated control
(dose 0).
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cells was toward HepG2 cells. Compared to the control
group, after 24 and 48 h of treatment with galangin at
concentrations between 0 and 5 μM, the cell viability
was not significantly altered, indicating galangin was not
toxic to HepG2 cells at these dosages. When cells were
treated with 10–30 μM galangin for 24 and 48 h, cell
viability was significantly reduced. These results demon-
strated that treatment with galangin at doses exceeding
5 μM for 24 and 48 h resulted in dose- and time-
dependent loss of cell viability in HepG2 cells; however,
treatment with doses lower than 5 μM for 24 and 48 h
did not cause cytotoxicity. Moreover, galangin did not
significantly inhibit the viability of Chang liver cells at
the same concentrations. Next, we used the HepG2 cellline to perform subsequent experiments, confirming that
treating HepG2 cells first with 70 nM TPA and then
with 5 μM galangin did not alter the viability and thereby
ensuring that the investigation of cell invasion and migra-
tion (described as follows) was reliable (Figure 1C).
Galangin inhibited TPA-induced cell adhesion,
morphology/actin cytoskeleton arrangement, invasion,
and migration in HepG2 cells
Cell adhesion, the binding of one cell to another cell or
to the ECM, is a critical process through which cancer
cells establish new tumours in the body. Therefore, we
used a cell-matrix adhesion assay to investigate the abil-
ity of galangin to inhibit cancer cell adhesion. After
treating cells with TPA for 12 h and with galangin in
Chien et al. Cancer Cell International  (2015) 15:15 Page 6 of 11various concentrations (1, 2.5, and 5 μM) for 24 h,
we observed that galangin inhibited the adhesion of
TPA-treated HepG2 cells in a dose-dependent manner
(Figure 2A); particularly, HepG2 cells were treated with
5 μM galangin for 24 h, exhibited substantial decreases in
cell adhesion ability.
To regulate migratory and invasive behaviour, tumour
cells must deform themselves, a process that requiresFigure 2 Effect of galangin on TPA-induced cell-matrix adhesion, cell
migration in HepG2 cells. Cells were treated with 70 nM TPA for 12 h an
for 24 h, and then were analysed for (A) cell-matrix adhesion, (B) immunof
bar: 100 μm, (D) transwell-chamber migration, scale bar: 100 μm, and (E) w
described in “Materials and methods” section. Values are expressed as mea
***p < 0.001 compared with the untreated control (dose 0).the activity of the cytoskeleton. Therefore, cytoskeleton
functions play vital roles in tumour cell growth, invasion
of surrounding tissue, and metastasis to new sites. We
used the immunofluorescence assay to investigate the in-
fluence of galangin on the morphology of cancer cells,
first treating HepG2 cells with TPA for 12 h and then
with galangin in various concentrations (1, 2.5, and
5 μM) for 24 h. A comparison of these cells to controlmorphology/actin cytoskeleton arrangement, invasion, and
d incubated in various concentrations of galangin (0, 1, 2.5, and 5 μM)
luorescence, scale bar: 20 μm, (C) transwell-chamber invasion, scale
ound-healing, scale bar: 100 μm. The aforementioned methods were
n ± SD of three independent experiments. *p < 0.05, **p < 0.01,
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of the HepG2 cells became elongated and contracted as
the concentration of galangin increased (Figure 2B).
Tumour invasion and migration are the primary causes
of morbidity in patients with cancer. To clarify the influ-
ence of galangin on the invasion ability and motility of
cancer cells, we used a transwell chamber invasion and
migration assay, observing that galangin (5 μM) signifi-
cantly inhibited TPA-induced invasion and migration by
64.3 % and 75%, respectively, compared with TPA treat-
ment alone (Figure 2C and D). Further examination the
effect of galangin on HepG2 cell migration was determined
using a wound-healing assay. As shown in Figure 2E, the
TPA-induced cell motility of HepG2 cells was significantly
increased compared to the untreated cells. Treatment with
1 or 2.5 μM galangin reduced the TPA-induced motility of
cells, and 5 μM galangin significantly blocked cell motility.
These results demonstrated that galangin may be used to
suppress tumour adhesion, F-actin patterns, and the inva-
sion and migration of highly metastatic HepG2 cells at
various concentrations.
Galangin inhibited TPA-induced MMP-2, MMP-9 enzyme
activity and mRNA expression in HepG2 cells
ECM degradation is crucial to cellular invasion, suggesting
that matrix-degrading proteinases determine whetherFigure 3 Effect of galangin on TPA-induced activity and expression o
TPA for 12 h in serum-free medium and then incubated in various concent
media were collected and MMP-2/MMP-9 activities were determined by ge
incubated in various concentrations of galangin (0, 1, 2.5, and 5 μM) for 12
semi-quantitative RT-PCR for MMP-2 and MMP-9 with GADPH being an inteMMP-2 and MMP-9 are involved in the inhibition of inva-
sion, motility, and adhesion of cancer cells by galangin;
therefore, we investigated the inhibitory effect of galangin
on TPA-induced MMP-2/-9 enzyme activity by using gel-
atin zymography under a condition of serum starvation.
Figure 3A showed that TPA significantly increased MMP-
2 and MMP-9 activity. In addition, galangin inhibited
MMP-2 and MMP-9 activity that was stimulated by TPA
in a concentration-dependent manner. To determine
whether the inhibition of MMP-2 and MMP-9 enzyme ac-
tivity by galangin was caused by the reduction of the tran-
scription level, we performed a RT-PCR and observed the
mRNA expression of MMP-2 and MMP-9. As shown in
Figure 3B, galangin reduced the TPA-induced MMP-2
and MMP-9 mRNA expression of HepG2 cells in a
dose-dependent manner. The data indicated that galan-
gin prevents the transcription of MMP-2 and MMP-9 in
response to TPA. These results suggested that the anti-
metastatic effect of galangin was related to the inhib-
ition of enzymatically degradative processes of tumour
metastasis.
Galangin inhibited TPA-induced the protein levels of
PKCα, PKCδ, and p-ERK1/2 in HepG2 cells
We investigated whether galangin inhibited TPA-induced
the expression of PKC family members in HepG2 cells.f MMP-2/MMP-9 in HepG2 cells. (A) Cells were treated with 70 nM
rations of galangin (0, 1, 2.5, and 5 μM) for 24 h. The conditioned
latin zymography. (B) Cells were treated with 70 nM TPA for 12 h and
h. And then, the RNA samples were extracted and subjected to a
rnal control.
Chien et al. Cancer Cell International  (2015) 15:15 Page 8 of 11This result of Western blot revealed that galangin inhib-
ited TPA-induced the protein levels of PKCα and PKCδ in
the time- and dose-dependent manners. No substantial
changes were observed in the protein levels of PKCβ,
PKCθ, PKCλ, and PKCμ. (Figure 4A and B).
Furthermore, we investigated the effect of galangin on
the phosphorylation of JNK1/2, ERK1/2, p38, and Akt in
cells stimulated by 70 nM TPA for 2 h. HepG2 cells
were then treated with various concentrations of galan-
gin for 6 h. Figure 4C showed that galangin significantly
inhibited TPA-induced ERK1/2 activation, indicated by
the decrease in the phosphorylation of ERK1/2. How-
ever, galangin did not significantly affect phospho-JNK,
phospho-p38, or phospho-Akt activity. Moreover, the
total protein levels of JNK1/2, ERK1/2, p38, and Akt did
not change after TPA and/or galangin treatment.Figure 4 Effect of galangin on TPA-induced the PKCα, PKCδ activation
with TPA (70 nM) for various times, the protein levels of PKCα, PKCβ, PKCδ,
(B) Cells were treated with various concentrations (0, 1, 2.5, and 5 μM) of g
levels of PKCα, PKCβ, PKCδ, PKCθ, PKCλ, and PKCμ in the membrane fractio
various concentrations (0, 1, 2.5, and 5 μM) of galangin for 6 h. The JNK ph
p38, Akt phosphorylation, and Akt were analysed by Western blotting. β-Actin
forms of JNK, ERK, and p38 were normalized to total values of JNK, ERK, and pGalangin-inhibited TPA-induced NF-κB and AP-1
transcriptional activation in HepG2 cells
NF-κB and AP-1 are the primary transcription factors
that regulate the expression of MMP enzymes in cells.
To investigate the association between NF-κB and AP-1
and the anticarcinogenic property of galangin, we ana-
lysed the ability of NF-κB and AP-1 bind to MMP-2/9
promoters by using an EMSA. As shown in Figure 5A
and B, the NF-κB and AP-1 DNA binding activity was
dramatically increased by TPA (70 nM) treatment, and
the TPA-stimulated NF-κB and AP-1 DNA binding ac-
tivity was strongly inhibited by galangin at 5 μM concen-
tration. Furthermore, the expressions of NF-κB, c-Fos,
and c-Jun in nuclear extracts was analysed using Western
blotting to assess the possible inhibitory effect of galangin.
Figure 5C shows that the nuclear levels of NF-κB, c-Fos,and ERK phosphorylation in HepG2 cells. (A) Cells were treated
PKCθ, PKCλ, and PKCμ in the membrane fraction were analyzed.
alangin in the presence or absence of TPA (70 nM) for 6 h, the protein
n was analysed. (C) Cells were treated with TPA (70 nM) for 2 h in
osphorylation, JNK, ERK phosphorylation, ERK, p38 phosphorylation,
was used as a loading control. The relative density of phosphorylated
38, which were determined by densitometric analysis.
Figure 5 Effect of galangin on the TPA-induced the DNA-binding activity of NF-κB and AP-1/expressions of NF-κB, c-Fos, c-Jun/IκBα
phosphorylation and degradation in HepG2 cells. Nuclear extracts were prepared from HepG2 cells that treated with various concentrations
of galangin (0, 1, 2.5, and 5 μM) in the presence of TPA (70 nM) for 12 h, and then used to analyze (A) NF-κB and (B) AP-1 DNA-binding activity
by EMSA, as described in “Materials and methods” section. Lane 1: nuclear extracts incubated with 100-fold excess unlabeled consensus
oligonucleotide (comp.) to confirm the binding specificity. Lane 2 represents nuclear extract from HepG2 cells in the absence of TPA (negative control).
(C) Nuclear or cytosolic extracts were subjected to SDS-PAGE followed by western blotting with specific antobodies (anti-NF-κB, anti-c-Fos, anti-c-Jun
anti-p-IκBα, anti-IκBα). C23 and β-actin were used as internal control.
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treatment when galangin doses of 1, 2.5, and 5 μM were
applied, and the TPA-stimulated nuclear protein expres-
sions NF-κB, c-Fos, and c-Jun were strongly inhibited by
galangin at 5 μM concentration. In addition, NF-κB was
activated through the phosphorylation of IκBα releasing
NF-κB for nuclear translocation, and for binding to the
promoter sites of target genes. The results showed that
galangin blocked TPA-induced IκBα degradation by inhi-
biting the phosphorylation of IκBα. Moreover, the inten-
sity of the bands on the Western blotting reflected that
galangin at a concentration of > 1 μM enhanced IκBα pro-
tein expression.
Discussion
For the past several decades, despite evolving manage-
ment and novel therapies for various types of cancers,
the prognosis for several types of cancers remain poor.
Because increasingly more researchers have dedicated
themselves to tumour research, the mechanisms underlyingthe oncogenesis and metastasis of cancer have gradually
been revealed, and additional anticarcinogenic compounds
have been discovered. Consequently, cancer chemopre-
vention for inhibiting the progression of cancer by using
certain compounds or mixtures, has become a potentially
viable method for treating cancer. Galangin is type of fla-
vonoid with the highest concentration levels amongst
Alpinia officinarum. Flavonoids are a vast group of hetero-
geneous polyphenols that are thought to exert positive
effects, including cancer prevention, on human health.
Various studies have shown that glangin exerts pleiotropic
anticancer effects, including preventive, anticarcinogenic,
and antiproliferative effects. In particular, glangin influ-
ences several processes and plays a crucial roles in regulat-
ing various molecular targets, including NF-κB [25,26],
Smads [27], peroxisome proliferator-activated receptor γ
(PPARγ) [28] transcription factors, tumour necrosis
factor-alpha (TNF-α), interleukins, intercellular adhesion
molecule-1 (ICAM-1), cyclooxygenase-2 (COX-2) [29-32],
JNK, p38 [25], and ERK [26]. Metastasis is a critical
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of signal transductions. When these signal pathways are
blocked with drugs or natural compounds, the spread of
cancer may be inhibited. The purpose of this study was to
determine whether galangin can inhibit HepG2 cancer cell
invasion, migration and adhesion, and to elucidate its
mechanism at a molecular level.
PKCs were shown to play key roles in various cellular
responses, including the regulation of gene expression
and the effects exerted on the cytoskeleton, cell growth,
and differentiation [33]. At least PKCs have recognised
and are typically distributed into three classes, namely
conventional (PKCα, βI, βII, γ), novel (δ, ε, ε’, η, θ, μ),
and atypical (ζ, λ/ι) PKCs. Amongst these three classes,
the activity of conventional PKCs depends on Ca+2, dia-
cyglycerol (DAG), or a phorbol ester analog of DNA
such as TPA [34-37]. Isozymes of the PKC family exert
various actions in cellular proliferation through a com-
plex network of signal transduction. Previous studied
have indicated that PKCα is a crucial signalling molecule
for MMP expression in tumor cells [38,39]. In addition,
PKCδ was shown to activate MMP expression [40]. We
found that galangin inhibited the mRNA expressions
and enzymic activity of MMP-2 and MMP-9 in HepG2
cells. These results suggested that decreases in the pro-
tein expression of PKCα and PKCδ are vital to the sup-
pression of MMP-2 and MMP-9 expression by galangin
in HepG2cells. The activation of PKC can lead to the ac-
tivation of MAPKs and the PI3K/Akt pathway. Our re-
sults revealed that long-term exposure to 70 nM TPA
leads to downregulation of PKC-α and PKC-δ in HepG2
cells, indicating that TPA is involved in the ERK1/2 sig-
nal transduction pathway. These findings indicated that
galangin inhibited TPA-induced MMP-2 and MMP-9
expression through the suppression of the PKC/ERK
pathway in HepG2 cells.
The transcription of MMP-2/-9 genes is regulated by
upstream sequences, including motifs corresponding to
NF-κB and AP-1 binding sites. NF-κB and AP-1 are acti-
vated in numerous pathological processes, including in-
flammation, cancer-cell adhesion, invasion, metastasis,
and angiogenesis. Previous studies have reported that
the MMP-2/-9 system plays a crucial role in breast can-
cer growth, invasion, and metastasis. In this study, we
found that treating HepG2 cells with galangin resulted
in inhibition of NF-κB and AP-1 DNA binding activity,
which was accompanied by inhibition of the nuclear
translocation of these factors.
Conclusions
In conclusion, our results reveal the first scientific evi-
dence showing that the suppression of the PKC/ERK path-
way by galangin downregulates TPA-induced MMP-2/-9
activation, thereby inhibiting migration and invasion inhuman HepG2 cells. Thus, galangin may be an effective
ingredient in agents developed for preventing cancer
metastasis.
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